Chimeric NKG2D CAR-expressing T cell-mediated attack of human ovarian cancer is enhanced by histone deacetylase inhibition

Human Gene Therapy

Volumn 24, Issue 3, 2013, Pages 295-305

  Song, De Gang ^a   Ye, Qunrui ^a   Santoro, Stephen ^a   Fang, Chongyun ^a   Best, Andrew ^a   Powell, Daniel J ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD137 ANTIGEN; CD3 ANTIGEN; LYMPHOCYTE ANTIGEN RECEPTOR; NATURAL KILLER CELL RECEPTOR NKG2D; VALPROIC ACID;

ANTIGEN RECOGNITION; ARTICLE; CANCER CELL CULTURE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL SURFACE; COCULTURE; CONTROLLED STUDY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNOTHERAPY; OVARY CANCER; PROTEIN TARGETING; T LYMPHOCYTE; UPREGULATION;

CELL LINE; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE ORDER; GENETIC VECTORS; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; IMMUNOPHENOTYPING; LENTIVIRUS; LIGANDS; LYMPHOCYTE ACTIVATION; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; OVARIAN NEOPLASMS; PHENOTYPE; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES; VALPROIC ACID;

EID: 84875455011     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2012.143     Document Type: Article

References (48)

1. Aoki, Y., Takakuwa, K., Kodama, S., et al. (1991). Use of adoptive transfer of tumor-infiltrating lymphocytes alone or in combination with cisplatin-containing chemotherapy in patients with epithelial ovarian cancer. Cancer Res. 51, 1934-1939.
2. Armeanu, S., Bitzer, M., Lauer, U.M., et al. (2005). Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res. 65, 6321-6329.
3. Barber, A., Zhang, T., Demars, L.R., et al. (2007). Chimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancer. Cancer Res. 67, 5003-5008.
4. Barrett, D.M., Zhao, Y., Liu, X., et al. (2011). Treatment of advanced leukemia in mice with mRNA engineered T cells. Hum. Gene Ther. 22, 1575-1586.
5. Berghuis, D., Schilham, M.W., Vos, H.I., et al. (2012). Histone deacetylase inhibitors enhance expression of NKG2D ligands in Ewing sarcoma and sensitize for natural killer cell-mediated cytolysis. Clin. Sarcoma Res. 2, 8.
6. Boise, L.H., Minn, A.J., Noel, P.J., et al. (1995). CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. Immunity 3, 87-98.
7. Carpenito, C., Milone, M.C., Hassan, R., et al. (2009). Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc. Natl. Acad. Sci. U.S.A. 106, 3360-3365.
8. Cerboni, C., Zingoni, A., Cippitelli, M., et al. (2007). Antigenactivated human T lymphocytes express cell-surface NKG2D ligands via an ATM/ATR-dependent mechanism and become susceptible to autologous NK-cell lysis. Blood 110, 606-615.
9. Chavez-Blanco, A., de la Cruz-Hernandez, E., Dominguez, G.I., et al. (2011). Upregulation of NKG2D ligands and enhanced natural killer cell cytotoxicity by hydralazine and valproate. Int. J. Oncol 39, 1491-1499.
10. di Stasi, A., Tey, S.K., Dotti, G., et al. (2011). Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med. 365, 1673-1683.
11. Dokmanovic, M., and Marks, P.A. (2005). Prospects: Histone deacetylase inhibitors. J. Cell Biochem. 96, 293-304.
12. Eagle, R.A., Traherne, J.A., Hair, J.R., et al. (2009). ULBP6/RAET1L is an additional human NKG2D ligand. Eur. J. Immunol. 39, 3207-3216.
13. Eshhar Z. (2008). The T-body approach: Redirecting T cells with antibody specificity. Handb. Exp. Pharmacol. 329-342
14. Fujita, K., Ikarashi, H., Takakuwa, K., et al. (1995). Prolonged disease-free period in patients with advanced epithelial ovarian cancer after adoptive transfer of tumor-infiltrating lymphocytes. Clin. Cancer Res. 1, 501-507.
15. Gonzalez, S., Lopez-Soto, A., Suarez-Alvarez, B., et al. (2008). NKG2D ligands: Key targets of the immune response. Trends Immunol. 29, 397-403.
16. Groh, V., Wu, J., Yee, C., and Spies, T. (2002). Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419, 734-738.
17. Gyobu, H., Tsuji, T., Suzuki, Y., et al. (2004). Generation and targeting of human tumor-specific Tc1 and Th1 cells transduced with a lentivirus containing a chimeric immunoglobulin T-cell receptor. Cancer Res. 64, 1490-1495.
18. Jemal, A., Siegel, R., Xu, J., and Ward, E. (2010). Cancer statistics, 2010. CA Cancer J. Clin. 60, 277-300.
19. Jensen, M.C., Popplewell, L., Cooper, L.J., et al. (2010). Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biol. Blood Marrow Transplant. 16, 1245-1256.
20. Junghans, R.P. (2010). Strategy escalation: An emerging paradigm for safe clinical development of T cell gene therapies. J. Transl. Med. 8, 55.
21. Kalos, M., Levine, B.L., Porter, D.L., et al. (2011). T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 3, 95ra73.
22. Kandalaft, L.E., Powell, D.J., Jr., Singh, N., and Coukos, G. (2011). Immunotherapy for ovarian cancer: What's next? J. Clin. Oncol. 29, 925-933.
23. Kershaw, M.H., Westwood, J.A., Parker, L.L., et al. (2006). A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res. 12, 6106-6115.
24. Kochenderfer, J.N., Wilson, W.H., Janik, J.E., et al. (2010). Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116, 4099-4102.
25. Kochenderfer, J.N., Dudley, M.E., Feldman, S.A., et al. (2012). B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119, 2709-2720.
26. Lai, P., Rabinowich, H., Crowley-Nowick, P.A., et al. (1996). Alterations in expression and function of signal-transducing proteins in tumor-associated T and natural killer cells in patients with ovarian carcinoma. Clin. Cancer Res. 2, 161-173.
27. Lamers, C.H.J., Willemsen, R., van Elzakker, P., et al. (2011). Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells. Blood 117, 72-82.
28. Langenkamp, U., Siegler, U., Jorger, S., et al. (2009). Human acute myeloid leukemia CD34+CD38-stem cells are susceptible to allorecognition and lysis by single KIR-expressing natural killer cells. Haematologica 94, 1590-1594.
29. Lehner, M., Gotz, G., Proff, J., et al. (2012). Redirecting T cells to Ewing's sarcoma family of tumors by a chimeric NKG2D receptor expressed by lentiviral transduction or mRNA transfection. PLoS One 7, e31210.
30. Leisegang, M., Wilde, S., Spranger, S., et al. (2010). MHCrestricted fratricide of human lymphocytes expressing survivin-specific transgenic T cell receptors. J. Clin. Invest. 120, 3869-3877.
31. Lo, A.S., Ma, Q., Liu, D.L., and Junghans, R.P. (2010). Anti-GD3 chimeric sFv-CD28/T-cell receptor f designer T cells for treatment of metastatic melanoma and other neuroectodermal tumors. Clin. Cancer Res. 16, 2769-2780.
32. Lockhart, D.C., Chan, A.K., Mak, S., et al. (2001). Loss of T-cell receptor-CD3f and T-cell function in tumor-infiltrating lymphocytes but not in tumor-associated lymphocytes in ovarian carcinoma. Surgery 129, 749-756.
33. Loskog, A., Giandomenico, V., Rossig, C., et al. (2006). Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells. Leukemia 20, 1819-1828.
34. Milone, M.C., Fish, J.D., Carpenito, C., et al. (2009). Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol. Ther. 17, 1453-1464.
35. Moeller, M., Kershaw, M.H., Cameron, R., et al. (2007). Sustained antigen-specific antitumor recall response mediated by genemodified CD4+ T helper-1 and CD8+ T cells. Cancer Res. 67, 11428-11437.
36. Molinero, L.L., Fuertes, M.B., Rabinovich, G.A., et al. (2002). Activation-induced expression of MICA on T lymphocytes involves engagement of CD3 and CD28. J. Leukoc. Biol. 71, 791-797.
37. Nausch, N., and Cerwenka, A. (2008). NKG2D ligands in tumor immunity. Oncogene 27, 5944-5958.
38. Parente-Pereira, A.C., Burnet, J., Ellison, D., et al. (2011). Trafficking of CAR-engineered human T cells following regional or systemic adoptive transfer in SCID beige mice. J. Clin. Immunol. 31, 710-718.
39. Parry, R.V., Rumbley, C.A., Vandenberghe, L.H., et al. (2003). CD28 and inducible costimulatory protein Src homology 2 binding domains show distinct regulation of phosphatidylinositol 3-kinase, Bcl-xL, and IL-2 expression in primary human CD4 T lymphocytes. J. Immunol. 171, 166-174.
40. Porter, D.L., Levine, B.L., Kalos, M., et al. (2011). Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725-733.
41. Savoldo, B., Ramos, C.A., Liu, E., et al. (2011). CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J. Clin. Invest. 121, 1822-1826.
42. Song, D.G., Ye, Q., Carpenito, C., et al. (2011). In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). Cancer Res. 71, 4617-4627.
43. Song, D.G., Ye, Q., Poussin, M., et al. (2012). CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo. Blood 119, 696-706.
44. Tanic, M., Yanowsky, K., Rodriguez-Antona, C., et al. (2012). Deregulated miRNAs in hereditary breast cancer revealed a role for miR-30c in regulating KRAS oncogene. PLoS One 7. e38847.
45. PLoS One 7, e38847. Theoret, M.R., Cohen, C.J., Nahvi, A.V., et al. (2008). Relationship of p53 overexpression on cancers and recognition by anti-p53 T cell receptor-transduced T cells. Hum. Gene Ther. 19, 1219-1232.
46. Verneris, M.R., Karami, M., Baker, J., et al. (2004). Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. Blood 103, 3065-3072.
47. Zhang, C., Wang, Y., Zhou, Z., et al. (2009). Sodium butyrate upregulates expression of NKG2D ligand MICA/B in HeLa and HepG2 cell lines and increases their susceptibility to NK lysis. Cancer Immunol. Immunother. 58, 1275-1285.
48. Zhang, L., Conejo-Garcia, J.R., Katsaros, D., et al. (2003). Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348, 203-213.